Invest Marketing Sales Thousand Oaks 
Xconomy
AUGUST 26, 2016
Two days later, it paid AstraZeneca $550 million upfront for the rights to a group of antibiotics either already on the market or in late-stage testing. The deal also includes a $175 million deferred payment due in 2019 and $850 million in downstream payouts tied to regulatory and sales targets.
Xconomy
AUGUST 5, 2016
Then came the rumor mill: Companies may or may not be approaching Biogen about a sale, and Biogen may or may not be fielding offers. As a result, Biogen will buy the rights to nusinersen and prepare to ask regulators for marketing approval. SMA has no approved treatments. Regeneron is paying $25 million upfront.
Expert insights. Personalized for you.
40 
Let's personalize your content